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Background: Endothelin-1 has been shown to be a mediator of pulmo- 
nary hypertension after cardiopulmonary b pass and deep hypothermic 
circulatory arrest. It is not known whether the mechanism is increased 
production of endothelin-1 or alterations in expression of endothelin-1 
receptors in the lung. This study was designed to test the hypothesis that 
circulatory arrest increases endothelin-1 mRNA levels and endothelin-1 
receptor expression in the lung. Methods and results: Twenty-four piglets 
(7 to 30 days old) were studied randomly either at baseline (controls, 
n = 12) or after cardiopulmonary b pass with 30 minutes of circulatory 
arrest (deep hypothermic circulatory arrest, n = 12). Lungs and 
pulmonary arteries were harvested immediately after hemodynamic data 
collection. Deep hypothermic irculatory arrest significantly increased 
pulmonary vascular esistance (p < 0.01). Deep hypothermic circulatory 
arrest also produced a significant increase in endothelin-1 mRNA levels 
in the pulmonary arteries (149 - 55 pg vs 547 - 111 pg, p = 0.007). 
There was no significant change in the pulmonary parenchymal endo- 
thelin-1 mRNA levels (4102 ± 379 pg vs 4623 _+ 308 pg, p = 0.32). 
Ligand binding studies of the lung parenchyma revealed a single specific 
endothelin-1 binding site with an ECso value (effective concentration 
causing 50% of the maximum response) of about 1 x 10 .8 tool/L, 
consistent with the endothelin B subtype. Deep hypothermic circulatory 
arrest resulted in a significant increase in the number of endothelin-1 
receptors in the lung (109 ± 6 fmol/mg total protein to 135 ± 9 fmol/mg 
total protein, p = 0.02). Conclusions: Deep hypothermic irculatory 
arrest increases production of endothelin-1 by the pulmonary vascular 
endothelium. Endothelin-1 production in the pulmonary parenchyma 
does not change. Expression of endothelin B receptors in the pulmonary 
parenchyma lso increases after cardiopulmonary bypass with deep 
hypothermic circulatory arrest. This study supports the hypothesis that 
deep hypothermic irculatory arrest results in pulmonary vascular 
endothelial activation with increased endothelin-1 mRNA production. 
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C ardiopulmonary bypass (CPB) with deep hypo- thermic circulatory arrest (DHCA) often results 
in clinically significant increases in pulmonary vas- 
cular resistance (PVR), particularly in infants and 
children. 1-4 Although clinically significant pulmo- 
nary dysfunction is uncommon, it can cause consid- 
erable morbidity and mortality in patients with 
impaired right ventricular function. The mecha- 
nisms underlying this response are still unclear. 
Previous studies have demonstrated the central 
role of the pulmonary vascular endothelium both in 
the maintenance of normal pulmonary vasomotor 
tone and in the hypertensive response to CPB. 2' 5-9 
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Impaired endothelium-dependent pulmonary vaso- 
dilation after CPB with DHCA has been demon- 
strated both in experimental nimals and in children 
undergoing repair of congenital cardiac defects. 2'7 
Increased production of endothelium-derived vaso- 
constrictors including endothelin-1 (ET-1) and 
thromboxane A2 has also been reported after CPB 
with DHCA. 5' s, t0 
ET-1 is a 21-amino acid polypeptide that is the 
most potent vasoconstrictor known. Plasma levels of 
ET-1 are elevated after CPB, TM 12 and blockade of 
ET-l-converting enzyme during CPB attenuates 
the post-DHCA pulmonary hypertensive r sponse. 6 
ET-1 is produced and released by endothelial cells 
with no intracellular storage. 13 Two ET-1 receptor 
subtypes are expressed in vascular tissue. The ET A 
receptor is expressed primarily by vascular smooth 
muscle cells whereas the ETB receptor is expressed 
by both endothelial cells and vascular smooth mus- 
cle cells. TM Activation of the ET A receptor esults in 
smooth muscle cell contraction and vasoconstriction 
because of phospholipase C stimulation and second- 
ary increases in intracellular calcium levels. Stimu- 
lation of ETB receptors on endothelial cells typically 
results in vasodilation through a nitric oxide-medi- 
ated pathway, t4 The relatively smaller numbers of 
ET B receptors found on vascular smooth muscle 
cells mediate vasoconstriction in a manner similar to 
that of ETA .15 
These studies were designed to test two hypothe- 
ses: (i) CPB with DHCA increases ET-t production 
by either the pulmonary vascular endothelium or the 
pulmonary parenchyma nd (2) CPB with DHCA 
increases pulmonary ET-1 receptor expression. 
ET-1 is transcriptionally regulated with no intracel- 
lular storage, thus endothelial production of ET-1 
can be quantitated by tissue ET-1 messenger ribo- 
nucleic acid (mRNA) levels. 
Methods 
Twenty-four DeKalb piglets (7 to 28 days old) were 
randomized into either the control or DHCA group. 
Control animals were studied after anesthesia nd instru- 
mentation were accomplished and DHCA animals also 
underwent CPB with DHCA as will be described. There 
was not a significant difference in the mean ages or 
weights of animals in the two groups. 
Anesthesia nd operation. The animals were premedi- 
cated with intramuscular ketamine (20 mg/kg) and 
acepromazine (1 mg/kg), intubated, and placed on me- 
chanical ventilation (Sechrist infant ventilator, model 
IV-100B). Anesthesia was maintained with fentanyl (100 
/xg/kg bolus and 50 ~g/kg per hour continuous infusion) 
and pancuronium (0.3 txg/kg). The ventilator was set with 
a positive inspiratory pressure of 25 mm Hg and a positive 
end-expiratory pressure of 3 mm Hg. Respiratory ate and 
inspired oxygen fraction were titrated to maintain an 
arterial carbon dioxide tension of 35 to 45 mm Hg and 
oxygen tension of 150 to 250 mm Hg. Sodium bicarbonate 
(8.5%) was used to maintain a base excess between -3 and 
3 mmol/L. All animals received methylprednisolone (25 
mg/kg intravenously) before operation. 
A femoral arterial line was placed for blood pressure 
monitoring and arterial blood gas sampling. A nasopha- 
ryngeal temperature probe (YSI-400, Yellow Springs In- 
struments) was inserted and a median sternotomy was 
done. The pericardium was opened and a 10 mm ultra- 
sonic flow probe placed on the main pulmonary artery 
(Transonic Systems Inc., Ithaca. N.Y.). Micromanometers 
(3F, Millar Instruments Inc.. Houston, Tex.) were placed 
in the pulmonary artery and left atrium. 
All animals received humane care in accordance with 
the "Guide for the Care and Use of Laboratory Animals" 
published by the National Institutes of Health (NIH 
Publication No. 85-23. revised 1985) and as approved by 
the institutional animal care and use committee. 
Protocol. DHCA-group animals underwent CPB with 
30 minutes of DHCA as will be described. Data were 
collected at baseline (before CPB) and 15 minutes after 
separation from CPB. Control animals underwent anes- 
thesia and instrumentation followed by data collection at 
baseline. After data collection at the last data point, all 
animals were killed. The pulmonary arteries and lungs 
were then excised and snap frozen in liquid nitrogen. 
Hemodynamic data collected included mean pulmonary 
arterial and left atrial pressures, cardiac index, and PVR, 
CPB and circulatory arrest. Purse-string sutures IEthi- 
con Inc.. Somerville, N.J.) were placed in the aortic root 
(5-0 Prolene suture) and right atrial appendage (2-0 silk). 
Animals were heparinized (500 IU/kg) and cannulated 
with a 10F infant arterial cannula and a 28F venous 
cannula (Electro-catheter Corp., Rahway, N.J J. The CPB 
circuit consisted of a Stockert Shiley roller pump (model 
10-10-00. Shiley Inc., Irvine, Calif.), Cobe membrane 
oxygenator (Cobe Laboratory, Lakewood. Colo.), and a 
Bio-Cal 370 heat exchanger (Biomedicus. Minneapolis. 
Minn.), The pump circuit was primed with crystalloid and 
fresh donor pig blood to maintain acircuit hematocrit of 
18% to 20%. 
The piglets were cooled over 20 minutes to a nasopha- 
ryngeal temperature of 18 ° C, the hearts were arrested for 
30 minutes, and the animals were then rewarmed over 30 
minutes to 37 ° C and weaned from CPB. Saline slush was 
used for topical myocardial hypothermia during cooling 
and circulatory arrest. The hearts became asystolic during 
cooling and occasionally fibrillated during rewarming, 
requiring direcl current cardioversion with 1 to 2 joules. 
No animal required more than two defibrillations. CPB 
circuit blood volume was returned to the animals as 
needed to maintain stable left atrial pressure and cardiac 
output after they were weaned from CPB. No inotropic 
agents were used Animals were studied 15 minutes after 
being weaned from CPB while in a steady-state condition 
with arterial blood gas values within the limits previously 
described in the anesthesia section. 
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Tissue RNA isolation. All tissue samples were stored at 
-70 ° C and kept on dry ice during handling. Total tissue 
RNA was isolated from lung parenchymal tissue and 
pulmonary arterial samples weighing between 400 and 700 
mg by the RNAzol method (RNA STAT-60, Tel-Test B, 
Inc., Friendswood, Tex.). RNA samples were quantitated 
with use of a spectrophotometer to measure absorbance at
260 and 280 nm. Twenty-microgram aliquots were stored 
at -70 ° C for later use. 
Complementary deoxyribonucleic acid constructs and 
RNA probes. The porcine ET-1 complementary deoxyri- 
bonucleic acid (cDNA) construct consists of a 0.328 kb 
EcoR1/BamH1 fragment in pSP73 (Promega, Madison, 
Wis.) encoding nucleotides 98-426 of the porcine ET-1 
gene. This fragment spans the region encoding the pre- 
pro-endotheiin gene. The control rat/3-actin cDNA con- 
struct used was a commercially available template con- 
taining a 0.126 kb I@nI/EcoR1 fragment in the 
pTRIPLEscript vector (Ambion Inc., Austin, Tex.). This 
fragment corresponds to exon 5 of the rat /3-actin gene 
(nucleotides 2682-2779 of Accession No. J00691/. 16 Lin- 
earized cDNA constructs were used to synthesize radio- 
labeled RNA anti-sense probes (32p-aCTP, NEN-Du- 
Pont, Boston, Mass.) and nonradiolabeled sense controls 
with the use of either T7 or SP6 RNA polymerase as 
previously described. 17 
RNase protection assay. The procedure originally de- 
scribed by Zinn, DiMaio, and Maniatis 18 with modifica- 
tions reported by Berkowitz and associates 19was used 
with the following additional modifications. In brief, 20/xg 
of total RNA was hybridized with 3 × 105cpm of ET-1 
probe and 4 × 105 cpm of simultaneously oaded rat 
~-actin control probe for 10 to 12 hours at 55 ° C. RNase 
A (40 /xg/ml) and T1 (1000 U/ml) were added to each 
sample and allowed to incubate for 1 hour at 30 ° C. After 
termination of the digestion with 10 /zl of 20% (weight/ 
volume) sodium dodecyl sulfate and 2.5/xl of proteinase K 
(15 mg/ml), the samples were ethanol-precipitated at 
-70 ° C overnight. The samples were then resuspended in
gel loading buffer, heated to 95°C for 5 minutes, and 
separated on a denaturing 8 mol/L urea/6% acrylamide 
gel (Sequagel sequencing system, National Diagnostics, 
Atlanta, Ga.). Gels were dried on Whatmann filter paper 
(Whatmann Inc., Maidstone, United Kingdom) and 
placed on a PhosphorImager screen for quantitation. 
Serial dilutions of ET-1 sense RNA (100 pg, I ng, 10 ng, 
20 ng, and 50 ng) were included with each hybridization 
assay to allow interpolation of the ET-1 mRNA concen- 
tration in the unknowns. The concentrations thus derived 
were then normalized with use of the/3-actin control tO 
correct for any loading or quantitation error. All samples 
were normalized to the mean of the /3-actin signals on 
each gel, with the belief that the mean would most closely 
approximate 20/xg of total RNA loaded. 
Endothelin protein assay. Samples of lung parenchyma 
weighing between 450 and 550 mg were homogenized with 
a polytron in 10 volumes (10 ml/gm) of 10% (volume/ 
volume) acetic acid. The specimens were centrifuged at 
20,000g for 15 minutes to remove precipitants. A commer- 
cial endothelin-l,2 radioimmunoassay kit (NEN Research 
Products, DuPont, Boston, Mass.) was used to measure 
the endothelin protein concentration i picograms per 
milligrams total protein. Total protein concentration was 
measured with the bicinchoninic acid method (BCA pro- 
tein assay, Pierce, Rockford, Ill.). 
Endothelin receptor ligand binding studies. Cell mem- 
branes were isolated from lung parenchymal specimens 
weighing 400 to 700 rag. The tissue was first homogenized 
with a polytron at 20,000 rpm for 2 to 3 minutes in lysis 
buffer containing 5 mmol/L Tris, 2 mmol/L ethylenedia- 
minetetraacetic a id, and the protease inhibitors oybean 
trypsin inhibitor (10 /xg/ml), benzamidine (10 /xg/ml), 
!eupeptin (10 p~g/ml), and bacitracin (200 /xg/ml). The 
homogenate was centrifuged at 19000g for 10 minutes and 
the pellet was resuspended in assay buffer (50 mmol/L 
Tris, 2 mmol/L MgC12, and protease inhibitors as just 
described) and filtered through a 210 ~m mesh filter 
(Spectra-mesh, VWR, Boston, Mass.). The protei n con- 
centration was determined by the bicinchoninic acid 
method. Stock solutions containing 1 rag/10 bd of buffer 
were stored at -70 ° C. The stock solutions were diluted 
1:10 with assay buffer and bovine serum albumin stock for 
a final bovine serum albumin concentration of 0.1%. 
Binding assays were done in triplicate on 80 to 100/xg 
of membrane proteins. Assays were conducted in a final 
volume of 250 /~1 of assay buffer with 125I-ET-1 at 80 
pmol/L final concentration. Unlabeled ET-1 or BQ123 
(10 .4 to 10 -14 mol/L final concentration) was added to the 
radioligand before the addition of the membrane proteins 
to generate competition curves. The binding reaction was 
incubated for 6 hours at 25 ° C. Bound tracer was then 
separated from free tracer by rapid vacuum filtration onto 
filter paper (glass fiber grade GFC, Whatmann Interna- 
tional). Filters were rinsed three times with 3 to 4 ml of 
4 ° C buffer (50 mmol/L Tris, pH 7.5) with use of a Brandel 
cell harvester (model M-48, Brandel Instruments, Gaith- 
ersburg, Md.). The bound radioactivity was measured in a 
gamma Counter (CobraII Autogamma, Packard, Meri- 
dien, Conn.). Saturation binding studies were done in 
identical fashion with either no unlabeled ligand (total 
binding) or 10 .6 mol/L unlabeled ET-1 (nonspecific bind- 
ing). 125I-ET-i was obtained from NEN-DuPont and both 
unlabeled ET-1 and BQ123 were obtained from Sigma 
Chemical (St. Louis, Mo.). 
Statistical analysis. Groups were compared by one- 
way analysis of variance with a p value less than 0.05 
considered significant. Statistical analysis was done with 
commercially available software (Sigmastat, Jandel Cor- 
poration, San Rafael, Calif.). All data are presented as 
means plus or minus the standard error of the mean. 
Results 
Hemodynamies and arterial blood gas values. 
There was no significant difference between control 
and DHCA group animals with regard to weight 
(6.7 _+ 1.2 kg vs 6.4 _+ 1.1 kg, p = 0.87). The arterial 
blood gas, pulmonary arterial pressure, cardiac in- 
dex, and PVR values immediately before tissue 
harvest are displayed in Table I. Although there was 
a statistically significant difference in the pH, this 
was not considered a clinically significant difference. 
There was no difference in the arterial oxygen or 
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Table I. Hemodynamic data 
Pco 2 Po 2 PAP CI PVR 
Group pH (ram Hg) (ram Hg) (ram Hg) (ml/kg/min) (dyne-sec-cm 5) 
Control 7.47 ± 0.01 35.3 ± 0.5 227 +_ 7 13.2 + 0.5 126 _+ 9 1447 _+ 264 
DHCA 7.43 ± 0.01" 34.8 + 0.7 224 _+ 7 23.9 +- 1.9" 110 ± 9 3088 ± 407* 
p Value 0.004 0.38 0.79 0.00005 0.22 0.003 
Pco2, Carbon dioxide tension; Po2, oxygen tension; PAP, pulmonary arterial pressure; CL cardiac index. 
*p < 0.05 DHCA vs control group (analysis of variance). 
Table II. Endothelin mRNA and protein levels 
PA ET-1 mRNA Lung ET-1 mRNA Lung ET-1 protein Lung ET-1 binding sites 
Group (pg) (pg) (pg/mg total protein) (fmoles/mg total protein) 
Control 149 ± 55 4102 +_ 379 4.4 +_ 0.2 109 _+ 6 
DHCA 547 _+ 111" 4623 ± 308 4.9 + 0.3 135 ± 9* 
p Value 0.007 0.13 0.13 0.02 
PA, Pulmonary arterial. 
*p < 0.05 DHCA vs control group (analysis of variance). 
carbon dioxide tensions. As would be expected, the 
pulmonary arterial pressure was significantly higher 
after DHCA (13.2 +_ 0.5 mm Hg vs 23.9 _+ 1.9 mm 
Hg, p = 0.00005). The elevation in pulmonary 
arterial pressure was associated with an increase in 
PVR whereas the cardiac index did not change 
significantly. 
RNA isolation. Sufficient otal RNA was isolated 
from the lung specimens of all 24 animals for 
analysis by RNase protection assay in duplicate. 
Unfortunately, given the small size of piglet pulmo- 
nary arterial specimens, there was insufficient RNA 
isolated from the pulm0riary artery of several ani- 
mals to allow for adequate analysis. The RNase 
protection assay data for the pulmonary artery is 
therefore based on 19 animals (9 control and 10 
DHCA). 
ET-1 mRNA and protein levels. The results of the 
RNase protection assays and ET-1 radioimmunoas- 
say are summarized in Table II. ET-i mRNA ex- 
pression was significantly increased after DHCA in 
the pulmonary artery (149 __ 55 pg vs 547 _+ 111 pg, 
p = 0.007), but there was no change in the lung 
parenchyma (4102 _+ 379 pg vs 4623 _+ 308 pg, p = 
0.32). There was not a statistically significan t change 
in pulmonary parenchymal ET-1 protein levels. 
Endothelin receptors in the lung. Representative 
competitive binding curves for a control piglet lung 
with unlabeled ET:I and BQ123 with 125I-ET-1 are 
shown in Fig. 1. These data are consistent with a 
single saturable ET-l-specific binding site with an 
approximate inhibition coefficient (Ki) of 5 to 10 
pmol/L. Binding was not inhibited by the ET A- 
specific antagonist BQ123 up to concentrations of 
10 -5 mmol/L. This is in contrast o representative 
curves from piglet aorta membranes (Fig. 2) in 
whiCh two ET-l-specific binding sites were present, 
one of which was BQ123 sensitive. These data 
suggest hat there is a single predominant ET-I- 
specific binding site present in parenchymal lung 
tissue and that this binding site is most likely one of 
the ET B receptor subtypes. 
Data from saturation binding studies are displayed 
in Table II. Data were collected from all 24 animals 
and all studies were conducted intriplicate. There was 
a significant increase in the number of ET-l-specific 
binding sites after DHCA (109 _+ 6 fmot/mg protein vs 
135 _+ 9 fmol/mg protein, p = 0.02). 
Discussion 
The mediators involved in the pulmonary hyper- 
tensive response to CPB with DHCA have been the 
focus of clinical and basic research for several years 
and considerable progress has been made in the 
identification of the mechanisms underlying this 
response. Pulmonary vasomotor tone is modulated 
by the vascular endothelium, which maintains a 
balance between vasodilators and vasoconstrictors. 
CPB with DHCA alters the balance by impairing 
endothelium-dependent vasodilation z 7, 9 and in- 
creasing production of vasoconstrictors,5, 6, 8,10 
which leads to pulmonary hypertension. Plasma 
levels of ET-1 are elevated after CPB TM 12; however, 
because 90% of ET-1 is secreted by the vascular 
endothelium toward the vessel media, a° the signifi- 
cance of increased plasma levels is unclear. Local 
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Fig. 1. Competition curves for specific 12SI-ET-I binding 
sites using (A) ET-1 and (B) BQ123 in piglet lung. CPM, 
Counts per minute; CPMo, counts per minute with no 
competitor (total binding). Representative curves of three 
experiments each done in triplicate are shown. 
concentrations of ET-1 are likely more important 
than circulating levels in determining the response 
of a vascular bed. This study demonstrate s that CPB 
with DHCA stimulates increased production of 
ET-1 by the pulmonary vascular endothelium. In the 
pulmonary vasculature, ET-1 may act as either a 
vasoconstrictor 2>23 or a vasodilator 24' 25 depending 
on the species, age, and baseline pulmonary vascular 
tone. Blockade of endothelin-converting enzyme 
during CPB with DHCA decreases the pulmonary 
hypertensive response, 6 which suggests that after 
CPB, ET-1 acts primarily as a pulmonary vasocon- 
strictor. 
This study also demonstrated increased expres- 
sion of ET-1 receptors in the pulmonary paren- 
chyma after CPB with DHCA. Previous reports 
have shown a heterogeneous distribution of ET-1 
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Fig. 2. Competition curves for specific 125I-ET-1 binding 
sites using (A) ET-1 and (B) BQ123 in piglet aorta. CPM,, 
Counts per minute; CPMo, counts per minute with no 
competitor (total binding). Representative curves of three 
experiments each done in triplicate are shown. 
receptor subtypes with both ET A and ETB receptors 
in the pulmonary artery and primarily ET B re- 
ceptors in the pulmonary parenchyma) 6'27 ET A 
receptors are expressed primarily on vascular 
smooth muscle cells and initiate second messenger 
systems leading to vasoconstriction. 28' 29 ET B recep- 
tors on vascular endothelial cells are responsible for 
the vasodilating effects of ET-1 through stimulation 
of endothelial nitric oxide production. ET B recep- 
tors on vascular smooth muscle cells, on the other 
hand, modulate vasoconstriction in some tis- 
sues. 14'29 The predominant endothelin receptor 
subtype found in the pulmonary parenchyma of the 
piglets in this study was ET B. The significance of the 
observed increase in ET B receptor expression in 
the lung parenchyma is not known. Stimulation of 
the ET B receptor on vascular smooth muscle cells 
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can lead to vasoconstriction, thus the increase in 
ETB receptor expression could facilitate the vaso- 
constrictor effects of ET-1. Becaue ET B receptors 
also may be responsible for ET-1 clearance by the 
lung, 30 the increase in pulmonary ETB receptor 
expression may represent a response to elevated 
plasma ET-1 levels. 
Although the results of this study are interesting, 
they must be interpreted within the limitations of 
the study design. As with all animal models, there 
may be significant differences between the piglet and 
human pulmonary vasculature; nonetheless, prior 
studies with this model have produced data consis- 
tent with clinica ! reports. Unfortunately, the pulmo- 
nary arterial specimens from these animals were not 
large enough to perform ET-1 protein and receptor 
studies in addition to mRNA isolation, thus the 
effects of CPB with DHCA on ET-1 receptor ex- 
pression in pulmonary arterial tissue cannot be 
determined from this study. Finally, although recep- 
tor density was evaluated in the pulmonary paren- 
chyma, the specific site of receptor expression within 
the lung tissue was not determined nor was receptor/ 
second messenger coupling assayed. 
The current study demonstrates increased pro- 
duction of ET-1 by the pulmonary vasculature and 
increased pulmonary parenchymal ET-1 receptor 
concentrations after CPB with DHCA. Previous 
studies have demonstrated impaired endothelium- 
dependent vasodilation after CPB with DHCA. 
These data suggest hat CPB with DHCA results in 
endothelial cell injury or activation, or both, that 
alters the balance between endothelium-derived 
vasodilators and vasoconstrictors. Impairment of 
endothelium-dependent vasodilation coupled with 
increased vasoconstrictor production results in pul- 
monary hypertension. 
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